347 related articles for article (PubMed ID: 34430359)
1. Detection of epidermal growth factor receptor (
Guo K; Shao C; Han L; Liu H; Ma Z; Yang Y; Feng Y; Pan M; Santarpia M; Carmo-Fonseca M; Silveira C; Lee KY; Han J; Li X; Yan X
Transl Lung Cancer Res; 2021 Jul; 10(7):3213-3225. PubMed ID: 34430359
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
[TBL] [Abstract][Full Text] [Related]
3.
Buder A; Hochmair MJ; Setinek U; Pirker R; Filipits M
Transl Lung Cancer Res; 2020 Apr; 9(2):239-245. PubMed ID: 32420063
[TBL] [Abstract][Full Text] [Related]
4. Detection of
Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
[TBL] [Abstract][Full Text] [Related]
5. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
[TBL] [Abstract][Full Text] [Related]
6. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
7. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
8. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
[TBL] [Abstract][Full Text] [Related]
9. Circulating free tumor-derived DNA to detect
Denis MG; Lafourcade MP; Le Garff G; Dayen C; Falchero L; Thomas P; Locher C; Oliviero G; Licour M; Reck M; Normanno N; Molinier O
J Thorac Dis; 2019 Apr; 11(4):1370-1378. PubMed ID: 31179079
[TBL] [Abstract][Full Text] [Related]
10. Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.
Long C; Li K; Liu Z; Zhang N; Xing X; Xu L; Gai F; Che N
Cancer Med; 2023 Apr; 12(7):7982-7991. PubMed ID: 36621813
[TBL] [Abstract][Full Text] [Related]
11. Comparison of
Jin J; He J; Yan X; Zhao Y; Zhang H; Zhuang K; Wen Y; Gao J
Am J Transl Res; 2022; 14(8):5605-5613. PubMed ID: 36105060
[TBL] [Abstract][Full Text] [Related]
12. Comparative Analysis of Two Methods for the Detection of
Hung MS; Lung JH; Lin YC; Fang YH; Huang SY; Jiang YY; Hsieh MJ; Tsai YH
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31185703
[TBL] [Abstract][Full Text] [Related]
13. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Wang W; Song Z; Zhang Y
Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
[TBL] [Abstract][Full Text] [Related]
15. Cross-Platform Comparison of Four Leading Technologies for Detecting
Xu T; Kang X; You X; Dai L; Tian D; Yan W; Yang Y; Xiong H; Liang Z; Zhao GQ; Lin S; Chen KN; Xu G
Theranostics; 2017; 7(6):1437-1446. PubMed ID: 28529628
[TBL] [Abstract][Full Text] [Related]
16. ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world setting.
Zhang S; Zhu L; Chen X; Zhang X; Chen E; Fang H; Feng Y; Li Y; Wang X; Jiang Z; Wang Y; Zhang Z; He H; Ma S
J Thorac Dis; 2018 Jul; 10(7):4169-4177. PubMed ID: 30174861
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
18. Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status.
Duan H; Lu J; Lu T; Gao J; Zhang J; Xu Y; Wang M; Wu H; Liang Z; Liu T
Int J Clin Exp Pathol; 2015; 8(10):13136-45. PubMed ID: 26722512
[TBL] [Abstract][Full Text] [Related]
19. Analysis of
Wang Y; Duan J; Chen H; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang S; Wang J
Oncol Lett; 2017 Apr; 13(4):2425-2431. PubMed ID: 28454414
[TBL] [Abstract][Full Text] [Related]
20. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
